Cardiovascular and renovascular implications of COX-2 inhibition

Current Pharmaceutical Design

Volumn 10, Issue 6, 2004, Pages 603-611

  Meagher, Emma A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Coxibs; Cyclooxygenase 2; Prostacyclin; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; LIGAND; LUMIRACOXIB; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTACYCLIN; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DRUG APPROVAL; DRUG CHOICE; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME INHIBITION; GASTRODUODENAL ULCER; GASTROINTESTINAL TOXICITY; GOUT; HEART INFARCTION; HEART PROTECTION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; KIDNEY FAILURE; OSTEOARTHRITIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RENOVASCULAR DISEASE; RENOVASCULAR HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; STOMACH OBSTRUCTION; STOMACH PROTECTION; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; UPPER GASTROINTESTINAL BLEEDING; VASOMOTOR REFLEX;

ANIMALS; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; HUMANS; KIDNEY; PROSTAGLANDINS; TREATMENT OUTCOME;

EID: 1442301510     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453153     Document Type: Review

References (71)

1. Celebrex (celecoxib). US Product Information, Pharmacia, Peapack, NJ 2001.
2. Goldenberg M. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 1999; 21: 1497-511
3. Scott L, Lamb H. Rofecoxib. Drugs 1999; 58: 499-507.
4. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-91.
5. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 1999; 274: 22903-6.
6. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
7. Wang LH, Hajibeigi A, Xu XM, Loose-Mitchell D, Wu KK. Characterization of the promoter of human prostaglandin H synthase-1 gene. Biochem Biophys Res Commun 1993; 190: 406-11.
8. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-60.
9. Bakhle YS, Butting RM. Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflamm 1996; 5: 305-23.
10. Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095-101.
11. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-91.
12. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci 2000; 902: 230-40.
13. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S. Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
14. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-41.
15. McAdam BF, Mardini IA. Habib A, Burke A, Lawson JA, Kapoor S, et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000; 105: 1473-82.
16. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-9.
17. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Upregulation of cyclooxygenase 2 by inhibition of cyclooxygenase 1: a key to nonsteroidal anti-inflammatory drug induced intestinal damage. J Pharm. Exp Therap 2002; 300: 754-61.
18. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287-94.
19. Reilly IA, FitzGerald GA. Inhibition of thromboxime formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-6.
20. Steering Committee of the Physicians' Health Study Research Group. Final Report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
21. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
22. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002; 110: 61-9.
23. FitzGerald GA. The choreography of cyclooxygenases in the kidney. J Clin Invest 2002; 110: 33-4.
24. Funk CD, Funk LB, Kennedy ME, Pong AS, FitzGerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991; 5: 2304-12.
25. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthase. J Pharmacol Exp Ther 1994; 271: 1705-12.
26. Cryer B, Feldman M, Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-21.
27. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563-8.
28. Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, et al. Characterization of rofecoxib as a cyclooxygenase-2 inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65: 336-47.
29. Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther 1999; 21:1653-63.
30. Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999; 94: 504-8.
31. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999; 282: 1921-8.
32. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000; 160: 1781-7.
33. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
34. Akashi H, Han HJ, Iizaka M, Nakamura Y. Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer 2000; 88: 873-80.
35. North GL. Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann Pharmacother 2001; 35: 1638-43.
36. Fournier DB, Gordon GB. Cox-2 and colon cancer: Potential targets for chemoprevention. J Cell Biochem 2000; 77: 97-102.
37. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
38. D716 mouse intestinal polyps. Cancer Res 2002; 62: 506-11.
39. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705-8.
40. Thomas T, Nadackal TG, Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 2001; 12: 3263-7.
41. Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, Kohno M, Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavengining of nitric oxide radicals. J Neurochem 2001; 76: 1895-904.
42. Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000; 57: 1586-91.
43. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal antiinflammatory drugs. N. Engl. J. Med. 1999; 340: 1888-99.
44. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83.
45. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
46. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group and E. Mortensen, Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000; 43: 370-7.
47. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of refecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
48. FDA Advisory CommitteeBriefing Information: NDA 21-042/s007 Vioxx (rofecoxib) (2001) Available at: http://www.fda.gov./ohrms/docket/ac/cdero/htm arthritis Accessed February 28, 2002.
49. FDA Advisory CommitteeBriefing Information: NDA 20-998/s009 Celebrex (celecoxib) (2001) Available at: http://www.fda.gov. Accessed February 28, 2002.
50. Juni P, Rutjes AW, Dieppe PA Are selective COX 2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-8.
51. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-8.
52. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-41.
53. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-51.
54. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 640-4.
55. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562-71.
56. Watson DJ, Rhodes T. Higher incidence of thromboembolic events among patients with rheumatoid arthritis vs. osteoarthritis, and vs. no arthritis, in the general practice research database (GPRD) Presented at the Annual European Congress of Rheumatology, Prague, Czech Republic (June 13-16, 2001) Abstract OP0109.
57. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280-8.
58. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109-20.
59. Kniff-Duttner EA, Martens A, vd Laar MA. Effects of nabumentone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 257-9.
60. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Strom B. Lower myocardial infarction risk amongst current users of non - aspirin non steroidal anti-inflammatory medications. J Amer Coll Cardiol 2002: 39; 318A (abstract).
61. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11: 382-7.
62. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9.
63. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118-3.
64. Cowley A, Mattson D, Lu S, Roman R. The renal medulla and hypertension. Hypertension 1995; 25: 663-73.
65. Nasjletti A. The role of eicosanoids in angiotensin dependent hypertension. Hypertension. 1998; 31: 194-200.
66. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133: 1-9.
67. Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999; 5: 217-20.
68. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal antiinflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 13443.
69. Graham GG, Graham RI, Day RO. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Curr Pharm Design 2002; 8(12): 1063-75.
70. Hawkey CJ, Skelly MM. Gastrointestinal safety of selective COX-2 inhibitors. Curr Pharm Design 2002; 8(12): 1077-89.
71. Martin MJ, Jimenez MD, Motilva V. New issues about nitric oxide and its effects on the gastrointestinal tract. Curr Pharm Design 2001; 7(10): 881-908.